IP Library Granted Patent US 11,439,701
Granted Patent B2
US 11,439,701 · App. 16/610,660 · Granted Sep 13, 2022

Bovine respiratory disease vaccine

Inventors: Lucas Huntimer (Greenfield, IN); Thomas Halbur (Greenfield, IN)
Assignee: Elanco US Inc
A61K39/145A61K39/102A61K39/295A61P31/16A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,439,701
App. No.
16/610,660
Granted
Sep 13, 2022
Kind
B2
Abstract

The present invention relates to vaccines for treating bovine respiratory disease. Such vaccines contain a combination of bovine influenza D virus and Mannheimia haemolytica antigens. An upper respiratory infection with an IDV leads to an increased potential for M. haemolytica pathology in the lungs. The vaccines may contain further antigens from other bovine respiratory pathogens.

Claims (13)

1. An immunogenic composition comprising a bovine influenza D virus antigen and a Mannheimia haemolytica antigen.

2. The immunogenic composition of claim 1 , wherein the Mannheimia haemolytica antigen is selected from the group of an inactivated bacterium, an extract of outer membrane proteins, and a recombinant leukotoxin, and any combination thereof.

3. The immunogenic composition of claim 1 , wherein the bovine influenza D virus antigen is an inactivated virus.

4. The immunogenic composition of claim 1 , wherein the bovine influenza D virus antigen is a modified, live virus.

5. The immunogenic composition of claim 4 , wherein the modified, live bovine influenza D virus antigen is a modified, live virus modified by codon deoptimization.

6. The immunogenic composition of claim 4 , wherein the modified, live bovine influenza D virus antigen comprises at least one codon-deoptimized genomic segment having a cDNA sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.

7. A vaccine for bovine respiratory disease comprising a bovine influenza D virus antigen and a Mannheimia haemolytica antigen, and a pharmaceutically acceptable excipient, stabilizer, solubilizer, or diluent, and optionally an adjuvant.

8. The vaccine of claim 7 , further comprising at least one antigen from an additional bovine pathogen.

9. The vaccine of claim 8 , wherein the additional bovine pathogen is selected from the group of bovine viral diarrhea virus (BVDV), bovine respiratory syncytia virus (BRSV), bovine herpesvirus (BHV), parainfluenza virus 3 (PB), Pasteurella multocida, Leptospira species, and Histophilus somni , and any combination thereof.

10. A method of treating or preventing bovine respiratory disease, comprising administering to a bovine the immunogenic composition of claim 1 .

11. The method of claim 10 , wherein the administering is done orally, intranasally, intratracheally, or by injection.

12. A method of treating or preventing bovine respiratory disease, comprising administering to a bovine the vaccine of claim 7 .

13. The method of claim 12 , wherein the administering is done orally, intranasally, intratracheally, or by injection.

Assignments (3)
ASSIGNMENT OF SECURITY INTEREST IN PATENT RIGHTS, RECORDED ON AUGUST 3, 2020, AT REEL/FRAME 053388/0967 Recorded Dec 3, 2025
From: GOLDMAN SACHS BANK USA, AS RETIRING COLLATERAL AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 073816/0021 →
SECURITY INTEREST Recorded Aug 3, 2020
From: ELANCO US INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 053388/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2019
From: HALBUR, THOMAS; HUNTIMER, LUCAS
To: ELANCO US INC.
Reel/Frame 050912/0078 →